MAY 23 ,2019

IMPORTANT BACKORDER INFORMATION

SUBJECT: Update regarding the backorder of OncoTICE®
(Bacillus Calmette-Guérin (BCG), Strain TICE®)

As communicated previously, due to manufacturing capacity constraint, OncoTICE® supply in Canada has been on allocation based on customers’ historical consumption since Oct 2018.

Recently we have been experiencing an unexpected manufacturing delay. The issue is expected to temporarily impact medication availability in Canada beginning late June till end of July 2019. During this time the medication will be temporarily unavailable in Canada.

The quality of the medicines manufactured by Merck is among our highest priorities. We recognize that the timing of this issue is particularly challenging given that the medication is already in limited supply due to increasing global demand. As the sole global supplier in many markets, Merck is committed to resolve the issue as quickly as possible and resuming manufacturing of the product to our maximum capabilities.

As part of our commitment to supporting the healthcare professionals and patients’ communities, we will continue to inform our customers of the availability of OncoTICE® (Bacillus Calmette-Guérin (BCG), Strain TICE®). Information of the availability of OncoTICE® (Bacillus Calmette-Guérin (BCG), Strain TICE®) is also available on www.DrugShortagesCanada.Ca.

Sincerely yours,

Catherine Galvin
Exec. Dir, Business Unit, Oncology
Merck Canada Inc

® Registered trademark of Merck Sharp & Dohme B.V. Used under license.